Biotech Firm Anocca Reveals the Story Behind Its Name
In a recent interview, Reagan Jarvis, chief executive of biotechnology firm Anocca, shared the story behind the company's distinctive name. Founded in 2013 by Jarvis and Mikael Blomqvist, Anocca develops precision T-cell immunotherapies to recognize cancer targets.
According to Jarvis, the name "Anocca" was chosen for its memorability and distinctiveness, while avoiding a too-sciencey tone. The company's focus on developing innovative treatments for cancer patients drove the decision-making process. "We wanted a name that would stand out in the industry," Jarvis explained. "Something that would be easy to remember and pronounce."
Anocca's origins date back to 2013, when Jarvis was working at the German Cancer Research Center in Heidelberg, Germany. It was during this time that he met Blomqvist, a Swedish entrepreneur with a track record of building successful companies. The two discussed the concept behind Anocca, which aimed to harness the power of precision T-cell immunotherapies to combat cancer.
T-cell immunotherapies work by training the body's immune system to recognize and attack cancer cells. This approach has shown promising results in clinical trials, with some patients experiencing complete remission from their disease. "Our goal is to make this treatment accessible to as many patients as possible," Jarvis said.
Anocca's research and development laboratories are based in Södertälje, Sweden, where a team of scientists and engineers work tirelessly to refine the company's treatments. Jonas Frey, senior bioengineer at Anocca, is one of those individuals. "We're constantly pushing the boundaries of what's possible with T-cell immunotherapies," he said.
The implications of Anocca's research are far-reaching, with potential applications in a range of fields beyond cancer treatment. "Our technology has the potential to revolutionize the way we approach disease diagnosis and treatment," Jarvis noted.
As Anocca continues to advance its research, the company remains committed to making precision T-cell immunotherapies available to patients worldwide. With a strong foundation and a clear vision for the future, Anocca is poised to make a significant impact in the biotechnology industry.
Background:
Anocca was co-founded by Reagan Jarvis and Mikael Blomqvist in 2013. The company's research focuses on developing precision T-cell immunotherapies to recognize cancer targets. Anocca's laboratories are based in Södertälje, Sweden.
Current Status:
Anocca continues to advance its research in precision T-cell immunotherapies. The company remains committed to making these treatments available to patients worldwide.
Next Developments:
As Anocca pushes the boundaries of what's possible with T-cell immunotherapies, the company is expected to announce significant breakthroughs in the coming months. Stay tuned for updates on this rapidly evolving field.
*Reporting by Nature.*
